Investigation of SGLT2 inhibitors for normal glucose tolerance

Investigation of SGLT2 inhibitors for normal glucose tolerance - Investigation of SGLT2 inhibitors for normal glucose tolerance

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013747

Enrollment

Registered

2014-05-15

Start date

2015-05-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

normal glucose tolerance

Interventions

Ipragliflozin 50mg 7days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Japanese having normal glucose tolerance 2 obtained written informed consent

Exclusion criteria

Exclusion criteria: 1) Type 1 DM (including SPIDDM) 2) Allergy for SGLT2 or Ipragliflozin 3) severe liver dysfunction 4) severe renal dysfunction 5) severe cardiac dysfunction 6) less than 20 years or over 61 years 7) pregnancy or breast feeding 8) mental retardation or dementia 9) systematic steroid administered 10) other inappropriate persons judged by investigators

Design outcomes

Primary

Measure	Time frame
parameter of insulin secretion(Insulinogenic index, HOMA-beta, AUC-IRI) parameter ofinsulin sensitivity (HOMA-R, Composite indexGIR)	—

Countries

Japan

Contacts

Public ContactKazuhiko Sakaguchi

Kobe university school of medicine Diabetes and Endocrinoplogy

kzhskskgc@med.kobe-u.ac.jp078-382-5861

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026